Key Takeaways
- Margins collapsed on one-time costs: EBITDA margin fell from 20.1% to 15% YoY in Q4, driven by an extraordinary spike in other expenditure from legal, professional, repairs, and advertising costs that management says will not recur at these levels.
- U.S. business missed guidance but the bottleneck is gone: FY23 U.S. revenue of ₹265.9 crores missed the ₹280–285 crores guided range because Plant 1 was under a warning letter, which has now been lifted, freeing capacity for regular shipments.
- Domestic business was flat as COVID tailwinds reversed: ATM and Karvol Plus alone dragged domestic revenue by ~₹40 crores annually, partly offset by ~₹15 crores from new launches, leaving the year flat despite strong prescription growth in core brands.
- Profit-share income is material and expected to recur: Q4 included ~₹16 crores in profit share (₹14 cr U.S., ₹2 cr Europe) from 4–5 products, and management is confident of maintaining ₹10–12 crores per quarter from U.S. profit share going forward.
- What to watch next quarter: Whether the U.S. business actually accelerates now that Plant 1 is available, the pace of margin recovery toward the 18–19% EBITDA guided for FY24, and any update on the sterile plant audit classification expected by mid-June.
Margin Walk: The Q4 Cost Spike
- One-time costs dominated the quarter: Legal and professional costs (~₹5 crores, 90–95% one-time) and elevated repairs drove the spike in other expenditure; management stated legal and professional and repairs is "definitely not a onetime thing, and we don't expect such high amounts going forward."
- Advertising spend was partly strategic, partly in sync with sales: Some portion of elevated advertising and sales promotion tracked prior-year India sales growth, while some was strategic one-time investment; with India business flat, management expects lower ASP going forward.
- Recurring cost step-up is manageable: After stripping out one-time items, ~₹5–10 crores per quarter is the new recurring cost base, which management expects to recover from incremental domestic and export sales.
- Forex impact was negligible: Q4 MTM loss was limited to ₹50 lakhs; hedging positions are favorable with the euro hedged at 93–93.5 versus market 89.5 and the pound at 105–106 versus market 102.
- FY24 margin commitment: Management is confident of delivering 18% to 19% EBITDA margin for FY24.
Pramod Ghorpade: "We have to take the cost in this particular period, while revenues will follow in following quarters."
U.S. Business: The Bottleneck Is Cleared
- The warning letter was the binding constraint: Plant 1 (solid dosage facility, Goa) was under a warning letter throughout FY23, limiting U.S. shipments; the warning letter has been lifted and the plant received EIR with VAI classification.
- Capacity is no longer the issue: With Plant 1 now available, existing products can be shipped from Plant 3 into Plant 1 and onward to the U.S.; management says "henceforth shipments will be very, very regular, and hence, there won't be any hiccups in future."
- FY23 missed guidance by ~₹15–20 crores: U.S. revenue came in at ₹265.9 crores against guidance of ₹280–285 crores; management attributes the miss to cautious product selection and decisions to postpone or not launch products based on business fundamentals.
- Base business erosion is a question management disputes: Per an analyst's math, on a QoQ comparable basis excluding the ₹16 crores profit share, the U.S. business has been eroding consistently; management said "I fail to understand where you're seeing the decline" and did not provide base business figures.
- Allopurinol alone is a ₹60+ crores product: Previously supplied only from Plant 3, the removal of the Plant 1 bottleneck means allopurinol can now be supplied from both sites; management expects it to easily do ₹60 crores this year.
- 3–4 U.S. approvals expected this year: Mostly ophthalmics, hardly one injectable, and at least one suspension; details on the suspension product's market size and competitive landscape were deferred to the Q2 call.
- The capacity upside takes two quarters: Management does not commit to a big change in one quarter because filings and approvals take time, but is "very confident by end of 2 quarters, you will see a big upside coming from Plant 1 availability."
- FY24 U.S. growth guidance: Management is "extremely confident" of 25% to 30% growth, citing a healthy order book.
Aditi Panandikar: "...against guidance, I guess, we have to be a little bit cautious now while giving guidance's because U.S. is that kind of market. If you are aware of what is happening with many of our peers, I think at Indoco, one thing you can rest upon, we are careful with our product selection and would like to play in this market to make money."
Profit-Share Income: A Recurring Stream
- Q4 profit share was diversified across products: The ~₹16 crores profit share (₹14 cr U.S., ₹2 cr Europe) came from 4–5 products, not solely brinzolamide; management declined to name the products.
- Steady-state expectation is ₹10–12 crores per quarter: Management is confident of maintaining this run rate; future molecules may not increase the profit-share amount because Indoco plans to retain IP and book profits directly in sales.
- Brinzolamide and Combigan will build on top: The larger SKU of brinzolamide launched in April (Q1 FY24); Combigan supply resolution is expected by October, with supply beginning then. Profit shares from both will start kicking in roughly two quarters after launch.
- Dossier income has structurally shifted: No out-license dossier income was booked in Q4 FY23 because Indoco is now keeping more dossiers for its own filing; Q4 last year had over ₹17 crores in dossier income.
Domestic Business: Flat Year, Recovery Bet
- COVID product reversal overwhelmed new launch success: ATM and Karvol Plus together impacted domestic business by ~₹40 crores annually, partly recovered by ~₹15 crores incremental from new launches; the net result was a flat year.
- New launches performed well: Dropizin (₹10 cr), Noxa (₹9 cr), Subitral (₹8 cr) featured in top 20 new launches; Ninaf clocked ₹1 crore in 40 days.
- Core brands showed strong prescription growth: Almost all top 20 brands posted robust double-digit prescription growth; Cyclopam jumped 27 ranks in top 300 IPM brands and delivered 17% primary growth and ~50% prescription growth.
- Volume growth was only 1% for the year: Management had expected higher single-digit growth in H2, but March underperformance caught up; part of the miss is attributed to MRs missing incentives and postponing sales to April, described as an alternative-year phenomenon.
- Organizational changes shed tail brands: The merger of CND and Focus divisions into Synergy led to letting go of certain tail brands, which also weighed on reported growth.
- FY24/FY25 India growth commitment: Management is confident of minimum 15% growth, with FY24/FY25 expected to be free of all COVID issues; corrective measures are being taken on MR performance but "cannot be timed to say that it will happen in 1 quarter, 2 quarter."
- Price increases will continue: Management expects to take the same 5% to 6% price increase in the coming year, taken at different times across products through the year.
International Markets: Europe and Emerging Markets
- Europe delivered 17.5% full-year growth: Lacosamide tablets garnered 30% market share and lacosamide injection 20% market share, both as first generics; allopurinol in Germany holds 70% market share, aided by a second consecutive AOK tender win.
- The German allopurinol tender is locked in through 2024: Indoco won the tender for the second time and will be the supplier for all of 2023 and 2024, with renewal up in January 2025; the product is expected to average ₹75–80 crores per year, up from ₹65 crores previously.
- Emerging markets had a catch-up quarter: Q4 performance was very strong after a lull in Q2 and Q3; Q1 may average out slightly lower, but from Q2 onwards performance is expected to be better than earlier years.
- South Africa, Australia, New Zealand grew 70% YoY to ₹10 crores in Q4.
- Europe high-potency and oncology launches are pending approval: Products are anytime due for approval; approval is expected early Q2 FY24, with contribution too early to quantify.
Manufacturing & Quality: Lessons from a Difficult Period
- The warning letter was a quality systems issue, not a product issue: Management emphasized that the warning letter related to quality management systems and compliance at the plant, and had nothing to do with any specific product.
- Sterile manufacturing challenges are real: Combigan supply issues are technical in nature; sterile ophthalmic and injectable manufacturing is described as difficult, with FDA-enforced changes on container closure systems requiring re-batching and re-filing. Since the products are owned by Teva, Indoco had to follow their guidance.
- Plant leadership has been restructured: The plant head position was elevated from GM to AVP about five years ago; there is now one head for sterile and one head for solid orals and liquid orals.
- Sterile plant audit classification is imminent: Expected by sometime mid-June.
- Capex plan is unchanged: Overall about ₹125 crores planned for coming years, in line with last guidance.
Aditi Panandikar: "It is not a child's play, and it is a very difficult manufacturing. Yes, where have we learned? Safe to assure you that we have learned more than any of our peers on what can go wrong especially matters beyond our control in the regulatory space."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin recovery | 18% to 19% EBITDA margin | FY24 |
| India business growth | Minimum 15% growth | FY24 and FY25 |
| U.S. business growth | 25% to 30% growth | FY24 |
| U.S. profit share | Maintain close to ₹10–12 crores per quarter | Quarterly through FY24 |
| Allopurinol U.S. revenue | Easily do ₹60 crores from that single product | FY24 |
| Allopurinol German tender | Average ₹75–80 crores per year | 2023 and 2024, with larger quantities than the previous tender |
| U.S. capacity upside | Big upside from Plant 1 availability | By end of 2 quarters |
| Combigan supply resolution | Supply should begin | By October |
| Brinzolamide larger SKU profit share | Profit shares start kicking in | 2 quarters after April launch |
| Combigan profit share | Profit shares start kicking in | 2 quarters after supply begins |
| Sterile plant audit classification | Classification expected | By mid-June |
| Europe high-potency/oncology approval | Approval expected | Early Q2 this year |
| Capex | ~₹125 crores | Coming years |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Net revenue | ₹428 cr, +6.9% YoY vs ₹400.3 cr |
| EBITDA margin | 15.0% at ₹64.2 cr, vs 20.1% at ₹80 cr YoY |
| PAT margin | 6.9% at ₹29.7 cr, vs 8.9% at ₹35.6 cr YoY |
| EPS | ₹2.75, vs ₹4.38 YoY |
| Domestic formulation revenue | ₹184.5 cr, -4.3% YoY vs ₹192.9 cr |
| International formulation revenue | ₹216 cr, +14.1% YoY vs ₹189.5 cr |
| US business revenue | ₹71.3 cr, +2.6% YoY vs ₹69.6 cr |
| Europe revenue | ₹82.1 cr, +3% YoY vs ₹79.7 cr |
| South Africa, Australia, New Zealand revenue | ₹10 cr, +70% YoY vs ₹5.9 cr |
| IPM sales (AWACS) | ₹299 cr, +13.6% YoY; rank 27, market share 0.68% |
| India branded portfolio price increase | 5% to 6% during FY23 |
| India business volume growth | 1% for the year gone by |
| US profit share | ₹14 cr in the quarter, spread across 2–3 products |
| Europe profit share | ₹2 cr in the quarter |
| Dossier income | Nil, vs over ₹17 cr in Q4 FY22 |
| MTM forex loss | ₹50 lakhs, vs heavy loss in Q3 |
| EBITDA margin guidance for FY24 | 18% to 19% |
| India business growth guidance for FY24/FY25 | Minimum 15% |
| US business growth guidance for current year | 25% to 30% |
| Capex plan for FY24 and FY25 | ~₹125 cr overall |